The critical role of MHC class II-mediated T-cell and B-cell priming for autoimmunity and the nonredundant roles of Cat S in peptide loading and MHC class II assembly prompted speculation that Cat S is a potential therapeutic target in SLE [18,25]. Here, CAT is linked to systemic lupus erythematosus.